News – Page 1077 – Endpoints News

SIGN UP

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

8 years ago

Brushing back biosims, a confident AbbVie outlines a blockbuster winning streak ahead for Humira

8 years ago

In a switch, Merck CEO signals he’s in a deal-making frame of mind

8 years ago

Biotech Peer Review: Magenta onboards five new VPs; BioInvent is hunting for a new CEO

8 years ago

First Celgene, now Gilead can’t accurately forecast drug sales revenue. How bad is this?

8 years ago

Tesaro wins FDA OK for an IV version of chemo drug, launches discovery deal with Evotec

8 years ago

PDL gets aggressive with an offer to buy out Neos Therapeutics

8 years ago

In a pre-Halloween fright show, Celgene just scared the hell out of Wall Street — shares crater

8 years ago

AbbVie boasts a PhIII sweep for top psoriasis contender risankizumab, but it has lots of competition

8 years ago

John Hood bags $90M for his quest to get fedratinib OK’d by FDA and catapult into the market

8 years ago

Amgen buries the last big CETP drug, marking the bitter end of a blockbuster quest

8 years ago

Yes, the FDA did just slap down PTC’s Duchenne MD drug for the third time

8 years ago

PDUFA date past, PTC still hasn’t said what the FDA’s verdict was; BioInvent searching for a new CEO

8 years ago

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

8 years ago

The Medicines Company brings out the ax, looking to jettison hundreds of jobs in top-to-bottom restructuring

8 years ago

Ablynx IPO raises $200M for its nanobody platform effort

8 years ago

Putting your subscription dollars to use: San Diego-based Brittany Meiling is joining Endpoints News

8 years ago

Publisher's note

As National Party Congress concludes, China’s FDA seeks to write widely-anticipated drug reforms into law

8 years ago

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics

8 years ago

What’s driving the rapid growth of the top 20 biopharma companies in the world?

8 years ago

Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx

8 years ago

Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO

8 years ago

In an update, Gilead spotlights top-line hits amid a mixed set of PhII data for its $600M NASH drug

8 years ago

Tiny hep B drug combo study touts potential of a ‘functional cure’ at little-known Replicor

8 years ago

First page Previous page 1074 1075 107610771078 1079 1080 Next page Last page